Dr. Reddy's Laboratories Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's has issued a clarification in response to news reports about a Delhi High Court ruling on Semaglutide. The company confirmed that this relates to an ongoing legal dispute with Danish drug maker Novo Nordisk over Semaglutide-containing products. On March 9, 2026, the Division Bench of the Delhi High Court upheld a previous Single-Judge order that permitted Dr. Reddy's to manufacture Semaglutide in India and export it to countries where Novo Nordisk does not hold a patent. The court refused to grant an interim injunction in Novo Nordisk's favour. The company noted that the matter remains sub-judice and does not constitute a material event requiring disclosure under SEBI Listing Regulations.
Positive for shareholders — Dr. Reddy's retains the right to manufacture and export Semaglutide (a high-demand diabetes and obesity drug) to non-Novo Nordisk patent markets, opening a significant revenue opportunity. However, the case is still ongoing, so the final outcome remains uncertain.